Skip to main content
. 2018 Dec 31;13(12):e0209932. doi: 10.1371/journal.pone.0209932

Table 2. Factors associated with treatment delay among patients with MDR-TB.

Variables Treatment Delay
n (%)
CRR (95% CI) ARR (95% CI)
Short delay Long delay
Sex
 Male 120 (56.1) 94 (43.9) 1.00 1.00
 Female 40 (34.5) 76 (65.5) 1.49 (1.10–2.02) * 1.40 (1.03–1.91) *
Age
 ≤ 30 years 66 (66.7) 33 (33.3) 1.00 1.00
 31–50 years 66 (40.7) 96 (59.3) 1.78 (1.19–2.64) * 1.71 (1.15–2.57) *
 > 50 years 28 (40.6) 41 (59.4) 1.78 (1.13–2.82) * 1.77 (1.11–2.82) *
Type of patient
 New case 9 (25.7) 26 (74.3) 1.00 1.00
 Previously treated case 151 (51.2) 144 (48.8) 0.66 (0.43–0.99) * 0.93 (0.58–1.50)
Contact with MDR-TB patient
 Absent 123 (58.0) 89 (42.0) 1.00 1.00
 Present 37 (31.4) 81 (68.6) 1.64 (1.21–2.21) * 1.48 (1.06–2.08) *
Diabetes mellitus
 Absent 152 (50.5) 149 (49.5) 1.00 1.00
 Present 8 (27.6) 21 (72.4) 1.46 (0.93–2.31) 1.09 (0.68–1.76)
HIV coinfection
 Absent 150 (50.3) 148 (49.7) 1.00 1.00
 Present 10 (31.3) 22 (68.8) 1.38 (0.89–2.17) 1.38 (0.87–2.18)
Residence
 Urban 129 (52.2) 118 (47.8) 1.00 1.00
 Rural 31 (37.3) 52 (62.7) 1.31 (0.95–1.82) 1.25 (0.89–1.73)

Sex, age, type of patient, contact with MDR-TB patient, diabetes mellitus, HIV coinfection, and residence were included in the model. Treatment delay was categorized into short (< 105 days) and long (≥ 105 days). Abbreviations: MDR-TB, multidrug-resistant tuberculosis; CRR, crude risk ratio; ARR, adjusted risk ratio.

* p value < 0.05 was significant